According to the ongoing Phase-III EMBER-3 trial (NCT04975308), the imlunestrant–abemaciclib combination significantly improves PFS compared to imlunestrant monotherapy in ER+/HER2− advanced breast cancer, regardless of ESR1 mutations (61). This evidence concerns the gene ESR1 and breast carcinoma.